Technical Analysis for AMGN - Amgen Inc.

Grade Last Price % Change Price Change
B 247.72 1.22% 2.98
AMGN closed up 1.22 percent on Friday, July 23, 2021, on 69 percent of normal volume.
Earnings due: Jul 26
*** please verify all earnings dates ***

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical AMGN trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Fell Below 20 DMA Bearish 1.22%
50 DMA Support Bullish 1.22%
Bollinger Band Squeeze Range Contraction 1.22%
Inside Day Range Contraction 1.22%
20 DMA Support Bullish 1.17%
50 DMA Support Bullish 1.17%
Bollinger Band Squeeze Range Contraction 1.17%
Shooting Star Candlestick Bearish 0.34%
Older End-of-Day Signals for AMGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Amgen Inc. Description

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Its principal products include Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body fight infections; Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body's response to inflammatory diseases; Aranesp and EPOGEN erythropoiesis-stimulating agents that stimulate the production of red blood cells; and XGEVA/Prolia (denosumab) to treat men with castration-resistant prostate cancer at high risk of developing bone metastases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides product candidates in mid- to late-stage development in various therapeutic areas comprising oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine, which includes neuroscience. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc; Takeda Pharmaceutical Company Limited; and UCB, as well as a strategic alliance with Astellas Pharma Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.


Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Medicine Biotechnology Nasdaq 100 Drugs Clinics Pharmaceutical Products Bone Monoclonal Antibody Inflammation Healthcare Providers Prostate Cancer Neuroscience Dow Jones Component Hematology Therapeutic Product Inflammatory Disease Inflammatory Diseases Dialysis Wholesale Distributor Wholesale Distributors Therapeutic Products Epidermal Growth Factor Receptor Takeda Pharmaceutical Company Red Blood Cell Blood Cells Nephrology Platelet Resistant Prostate Cancer Cancer Care Metastases Growth Factors Mimics Recombinant Proteins Tumor Necrosis Factor Bone Disease Necrosis Thousand Oaks Castration Resistant Prostate Cancer Human Therapeutic Products Tumor Necrosis

Is AMGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 276.69
52 Week Low 210.28
Average Volume 2,312,947
200-Day Moving Average 238.66
50-Day Moving Average 243.30
20-Day Moving Average 245.16
10-Day Moving Average 245.94
Average True Range 4.00
ADX 14.41
+DI 23.62
-DI 18.13
Chandelier Exit (Long, 3 ATRs) 238.39
Chandelier Exit (Short, 3 ATRs) 248.93
Upper Bollinger Bands 248.80
Lower Bollinger Band 241.51
Percent B (%b) 0.85
BandWidth 2.97
MACD Line 1.04
MACD Signal Line 0.92
MACD Histogram 0.1232
Fundamentals Value
Market Cap 144.21 Billion
Num Shares 582 Million
EPS 12.40
Price-to-Earnings (P/E) Ratio 19.98
Price-to-Sales 5.34
Price-to-Book 11.94
PEG Ratio 1.48
Dividend 6.40
Dividend Yield 2.58%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 253.21
Resistance 3 (R3) 252.87 250.70 252.30
Resistance 2 (R2) 250.70 249.30 250.87 251.99
Resistance 1 (R1) 249.21 248.44 249.96 249.55 251.68
Pivot Point 247.04 247.04 247.41 247.21 247.04
Support 1 (S1) 245.55 245.64 246.30 245.89 243.76
Support 2 (S2) 243.38 244.78 243.55 243.45
Support 3 (S3) 241.89 243.38 243.15
Support 4 (S4) 242.23